Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)

Phase 2Completed

2 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Submassive Pulmonary Embolism

Conditions

Submassive Pulmonary Embolism

Trial Timeline

Sep 1, 2004 → Jan 1, 2008

NCT ID

NCT00191724

About Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)

Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) is a phase 2 stage product being developed by Eli Lilly for Submassive Pulmonary Embolism. The current trial status is completed. This product is registered under clinical trial identifier NCT00191724. Target conditions include Submassive Pulmonary Embolism.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00191724	Phase 2	Completed	Sep 1, 2004	Jan 1, 2008	Submassive Pulmonary Embolism